Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion

Drug Metabolism and Disposition

Volumn 25, Issue 5, 1997, Pages 610-616

  Chow, Fung Sing ^a   Piekoszewski, Wojciech ^a,b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; ERYTHROCYTE; HEMATOCRIT; HUMAN; HUMAN CELL; LIVER CLEARANCE; LIVER PERFUSION; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RABBIT;

ANIMALS; CATTLE; ERYTHROCYTES; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; METABOLIC CLEARANCE RATE; PERFUSION; RABBITS; SERUM ALBUMIN; TACROLIMUS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030984839     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. A. Abu-Elmagd, J. J. Fung, M. Alessiani, A. Jain, S. Takaya, R. Venkataramanan, V. S. Warty, W. Shannon, S. Todo, A. G. Tzakis, D. Van Thiel, and T. E. Starzl: Strategy of FK 506 therapy in liver transplant patients: Effect of graft function. Transplant. Proc. 23, 2771-2774 (1991).
2. A. Motabarrik, S. Takahara, Y. Kokado, H. Kemeoka, Y. Takano, D. Zaid, T. Sonoda, A. Okuyama, and M. Ishibashi: Use of FK 506 in kidney transplantation. Transplant. Proc. 25, 2250-2252 (1993).
3. S. Todo, A. G. Tzakis, J. Reyes, A. Abu-Elmagd, A. Casavilla, J. J. Fung, and T. E. Starzl: Intestinal transplantation in humans under FK 506. Transplant. Proc. 25, 1198-1199 (1993).
4. R. Venkataramanan, A. Jain, E. Cadoff, V. S. Warty, K. Iwasaki, K. Nagase, A. Krajack, O. Inventarza, S. Todo, J. J. Fung, and T. E. Starzl: Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant. Proc. 22, 55-56 (1990).
5. B. G. Ericzon, B. Ekqvist, C. G. Groth, and J. Save: Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. Transplant. Proc. 23, 2775-2776 (1991).
6. A. Jain, R. Venkataramanan, S. Todo, A. Abu-Elmagd, J. J. Fung, V. S. Warty, A. G. Tzakis, J. Reyes, M. Alessiani, and T. E. Starzl: Intravenous, oral pharmacokinetics, and oral dosing V of FK 506 in small bowel transplant patients. Transplant. Proc. 24, 1181-1182 (1992).
7. W. J. Jusko, W. Piekoszewski, G. B. Klintmalm, M. Schaeffer, M. F. Hebert, A. A. Piergies, Ch. Lee, P. Schechter, and Q. A. Mekki: Pharmacokinetics of tacrolimus (FK 506) in liver transplant patients. Clin. Pharmacol. Ther. 57, 281-290 (1995).
8. K. Takada, H. Usuda, M. Oh-Hashi, H. Yoshikawa, S. Muranishi, and H. Tanaka: Pharmacokinetics of FK 506, a novel immunosuppressant after intravenous and oral administration in rats. J. Pharmacobiodyn. 14, 34-42 (1991).
9. K. Iwasaki, T. Shiraga, K. Nagase, K. Hirano, K. Nozaki, and K. Noda: Pharmacokinetic study of FK 506 in the rat. Transplant. Proc. 23, 2757-2759 (1991).
10. W. Piekoszewski, F. S. Chow, and W. J. Jusko: Disposition of tacrolimus (FK 506) in rabbits: role of red cell binding in hepatic clearance. Drug Metab. Dispos. 21, 690-698 (1993).
11. W. Piekoszewski, F. S. Chow, and W. J. Jusko: Pharmacokinetic and pharmacodynamic effect of coadministration of methylprednisolone and tacrolimus in rabbits. J. Pharmacol. Exp. Ther. 269, 103-109 (1994).
12. K. S. Pang: Liver perfusion studies. In "Drug Metabolism and Drug Toxicity" (J. R. Mitchell and M. G. Horning, eds.), pp. 331-352. Raven Press, New York, 1984.
13. K. Tamura, M. Kobayashi, K. Hashimoto, K. Kojima, K. Nagase, K. Iwasaki, T. Kaizu, H. Tanaka, and M. Niwa: A highly sensitive method to assay FK 506 levels in plasma. Transplant. Proc. 19, 23-29 (1987).
14. W. J. Jusko and R. D'Ambrosio: Monitoring FK 506 concentrations in plasma and whole blood. Transplant. Proc. 23, 2732-2735 (1991).
15. W. T. Vetterling, S. A. Teukolsky, W. H. Press, and B. P. Flannery: Root finding and nonlinear sets of equations. In "Numerical Recipes," 2nd ed., pp. 124. Cambridge University Press, New York, 1994.
16. M. Machida, S. Takahara, M. Ishibashi, M. Hayashi, T. Sekihara, and H. Yamanaka: Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant. Proc. 23, 2753-2754 (1991).
17. W. Piekoszewski and W. J. Jusko: Plasma protein binding of tacrolimus in humans. J. Pharm. Sci. 82, 340-341 (1993).
18. N. Rifai, F. Chao, Q. Pham, J. Thiessen, and S. Soldin: The role of lipoproteins in the transport and uptake of cyclosporine and dihydrotacrolimus into HepG2 and JURKAT cell lines. Clin. Biochem. 29, 149-155 (1996).
19. A. H. Trung, G. Sirois, L. M. Dube, and I. J. McGilveray: Comparison of the erythrocyte partitioning method with two classical methods for estimating free drug fraction in plasma. Biopharm. Drug Dispos. 5, 281-290 (1994).
20. J. Siekierka, S. Hung, M. Poe, C. Lin, and H. Sigal: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341, 755-757 (1989).
21. J. Kay, E. Kwateng, F. Geraghty, and G. Morgan: Uptake of FK506 by lymphocytes and erythrocytes. Transplant. Proc. 23, 2760-2762 (1991).
22. E. Cunningham: The human erythrocyte membrane contains a novel 12-kDa inositol phosphate-binding protein that is an immunophilin. Biochem. Biophy. Res. Comm. 215, 212-218 (1995).
23. S. Øie and T. W. Guentert: Comparison of equilibration times in dialysis experiments using spiked plasma or spiked buffer. J. Pharm. Sci. 71, 127-128 (1982).
24. J. H. Lin, T. H. Lin, and H Cheng: Uptake and stereoselective binding of the enantiomers of MK-927, a potent carbonic anhydrase inhibitor by human erythrocytes in vitro. Pharm. Res. 9, 339-344 (1992).